435 Studies Now Enrolling
A PHASE 1B, OPEN-LABEL, MULTI-CENTER, DOSE-ESCALATION STUDY OF THE SAFETY, PHARMACOKINETICS, AND THERAPEUTIC ACTIVITY OF CERGUTUZUMAB AMUNALEUKIN, AN IMMUNOCYTOKINE, WHICH CONSISTS OF A VARIANT OF INTERLEUKIN-2 (IL-2v) TARGETING CARCINOEMBRYONIC ANTIGEN (CEA), AND ATEZOLIZUMAB, AN ANTIBODY TARGETING PROGRAMMED DEATH-LIGAND 1 (PD-L1) ADMINISTERED IN COMBINATION INTRAVENOUSLY, IN PATIENTS WITH LOCALLY ADVANCED AND/OR METASTATIC SOLID TUMORS
Study of Drug in Non-Small Cell Lung Cancer
| Sponsor: | F. Hoffmann- La Roche Ltd. |
| Enrolling: | Male and Female Patients |
| IRB Number: | AAAR5186 |
| U.S. Govt. ID: | NCT02350673 |
| Contact: | Naiyer Rizvi MD: 646-317-3141 / nar2144@cumc.columbia.edu |
Additional Study Information:
The purpose of this study is to test the safety of the study drugs and how well your body tolerates it. The study will also test how well the study drugs work to slow down the growth of you tumor or stop your cancer. The study drugs are Cergutuzumab Amunaleukin and Atezolizumab. Atezolizumab is FDA approved for the treatment of patients with metastatic non-small cell lung cancer. Cergutuzumab Amunaleukin is an investigational new drug that has not been approved for treatment.
This study is closed